Objective To explore the effects of Zuogui pill on P38 mitogen-activated protein kinase (MAPK) signaling pathway and cognitive function in patients with Parkinson's disease-mild cognitive impairment (PD-MCI). Methods A total of 80 patients with liver and kidney Yin deficiency type of PD-MCI in conformity with the inclusion criteria were selected from and randomly divided into the observation and control group,with 40 cases in each group. The control group was treated with butylphthalein softgel,and the observation group was treated with Zuogui pills. After 8 weeks of treatment,the curative effect,TCM syndrome scores and P38 MAPK signaling pathway expression,cognitive behavioral function[with ADL,MMSE and Montreal Cognitive Assessment Scale ( MoCA )],levels difference of inflammatory response[with UA,homocysteine ( Hcy )]of the patients were all observed. The differences in adverse reactions during treatment were analyzed in both groups. Results The observation group had a higher overall effective rate (P<0.05) than the control group. After 8 weeks of treatment,the scores of head or limb vibration,limb cramping,neck and back stiffness,waist and knee pain,flank pain,dizziness and headache of the 2 groups were lower than before treatment,and the observation group was lower than the control group (P<0.05). The expression of P38 MAPK and P-JNK protein in 2 groups decreased compared with that before treatment,and the observation group was lower than the control group (P<0.05). Compared with before treatment,MMSE and MoCA scores of the patients with liver and kidney Yin deficiency type of PD-MCI in both groups increased and ADL scores decreased after 8 weeks of treatment. MMSE and MoCA scores in observation group were higher than those in control group,while ADL scores in observation group were lower than those in control group (P<0.05). Compared with before treatment,UA increased and Hcy decreased in the two groups in the 8 th week of treatment. Hcy in the observation group was lower than that in the control group ( P<0.05 ),and there was no significant difference in UA between the two groups ( P>0.05 ).There was no difference in the incidence of adverse reactions (P>0.05). Conclusion Zuogui pill combined with butyphthalide in the treatment of PD-MCI is contribute to the efficacy,and it can regulate the P38 MAPK signaling pathway,improve the cognitive function and reduce the inflammation level,and it does not increase the adverse reactions.
维普
万方数据